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Deep sequencing of blood and gut 
T-cell receptor β-chains reveals 
gluten-induced immune signatures 
in celiac disease
Dawit A. Yohannes1,2, Tobias L. Freitag1,3, Andrea de Kauwe1,2, Katri Kaukinen4,  
Kalle Kurppa5, Pirjo Wacklin6, Markku Mäki5, T. Petteri Arstila1,3, Robert P. Anderson7,9,  
Dario Greco8,10 & Päivi Saavalainen1,2
Celiac disease (CD) patients mount an abnormal immune response to gluten. T-cell receptor (TCR) 
repertoires directed to some immunodominant gluten peptides have previously been described, but 
the global immune response to in vivo gluten exposure in CD has not been systematically investigated 
yet. Here, we characterized signatures associated with gluten directed immune activity and identified 
gluten-induced T-cell clonotypes from total blood and gut TCR repertoires in an unbiased manner using 
immunosequencing. CD patient total TCR repertoires showed increased overlap and substantially 
altered TRBV-gene usage in both blood and gut samples, and increased diversity in the gut during 
gluten exposure. Using differential abundance analysis, we identified gluten-induced clonotypes in 
each patient that were composed of a large private and an important public component. Hierarchical 
clustering of public clonotypes associated with dietary gluten exposure identified subsets of highly 
similar clonotypes, the most proliferative of which showing significant enrichment for the motif ASS[LF]
R[SW][TD][DT][TE][QA][YF] in PBMC repertoires. These results show that CD-associated clonotypes 
can be identified and that common gluten associated immune response features can be characterized in 
vivo from total repertoires, with potential use in disease stratification and monitoring.
Celiac disease (CD) is a complex disorder with an overall estimated prevalence of 1% among people of European 
ancestry1. It is characterized by small intestinal villous atrophy leading to nutrient malabsorption but may man-
ifest with a wide range of gastrointestinal and extra-intestinal symptoms. In patients, cereals containing gluten, 
in particular wheat, barley and rye, activate gluten-specific immunity leading to disease relapse. Consequently, a 
strict life-long gluten free diet (GFD) is currently the only available treatment for CD.
The most important genetic determinants for susceptibility to CD are Human Leukocyte Antigen (HLA) 
alleles. About 90% of CD patients carry HLA-DQA1*05 and -DQB1*02 that together encode HLA-DQ2.5, while 
the remainder carry HLA-DQA1*0301 and -DQB1*0302 (HLA-DQ8), and/or HLA-DQA1*02 and -DQB1*02 
(HLA-DQ2.2). HLA-DQ2.5, DQ2.2 and/or DQ8 are found in about half of the general population and are neces-
sary but not sufficient for developing the disease.
CD4+ T-helper cells specific for gluten epitopes presented by HLA-DQ2.5, HLA-DQ2.2, or HLA-DQ8 are 
considered central to the pathogenesis of CD2. Systemic administration of peptides with immunodominant 
epitopes for gluten-specific CD4+ T-cells causes digestive symptoms that are typically associated with glu-
ten ingestion3. CD4+ T-cells specific for gluten are present in the small intestine2 and circulate at increased 
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frequencies six days after gluten reintroduction4. Peripheral blood collected after short-term gluten challenge har-
bours expanded populations of gut-homing, effector memory, CD4+ T-cells specific for gluten. In HLA-DQ2.5+ 
CD patients, gluten-reactive CD4+ T-cells detected in blood by IFNγ ELISpot after short-term wheat, barley or 
rye challenge preferentially target immunodominant epitopes in one of three short peptides5. Gluten challenge 
in CD patients also increases the frequencies of CD8+ αβ and γδ T-cells, but their antigen specificities have not 
been determined6–8.
CD4+ effector T-cells in blood specific for the most commonly recognized epitopes, HLA-DQ2.5-glia-α2 
and HLA-DQ2.5-glia-ω2, show biased but distinct pairing of T-cell receptor(TCR)α and TCRβ genes: TRBV7-
2 with TRAV26-1 in T-cells specific for HLA-DQ2.5-glia-α2, and TRBV4 with TRAV4 in T cells specific for 
HLA-DQ2.5-glia-ω29–11. CD4+ T-cells specific for either of these epitopes showed features of antigen driven 
selection such as convergent recombination and semi-public response9–11. The semi-public response suggests a 
common disease mechanism across patients, since random clonotype sharing between individuals is unlikely, 
owing to the highly diverse T-cell repertoire in individuals generated via the V(D)J recombination machinery12–14. 
Another subset of gluten reactive CD4+ T-cells specific for HLA-DQ2.5-glia-α1a had a biased usage of TRBV20-
1 or TRBV29-115. Similarly, in HLA-DQ8+ CD patients, HLA-DQ8-restricted gluten reactive T-cells show biased 
usage of TRBV9-116.
Despite such detailed characterizations of isolated T-cells specific for selected immunodominant gluten pep-
tides, a global view of the TCR repertoire directed to in vivo gluten exposure is lacking.
Advances in next generation sequencing (NGS) now provide an opportunity to explore the full T-cell response 
induced by gluten irrespective of whether gluten or other antigens are targeted. This novel approach could pro-
vide extensive detail complementary to what has been learned from gliadin-tetramer based approaches8–11,17 and 
systematic gluten epitope mapping studies5,18. In this study, we applied deep TCRB CDR3 sequencing to charac-
terize CD patient immune repertoires during gluten exposure, and to identify gluten reactive T-cell clonotypes 
in an unbiased manner.
Results
TCR repertoire data was generated from subjects in three experiments (Table 1 and Supplementary Table S1). We 
obtained an average of 14694 unique productive nucleotide TCRB clonotypes from 544066 reads for each pre- 
oral gluten challenge (day 0) and post-challenge (day 6) patient PBMC sample. For the gut biopsy samples, there 
was an average of 8784 unique productive nucleotide TCRB clonotypes from 1414060 reads per patient sample. 
Clonotypes from the gut were bigger in size (reads/clone) compared to clonotypes in PBMC repertoires, reflect-
ing differences in the proportion of naive and memory T-cells in the tissues (Supplementary Table S1). For sorted 
samples with CD4+ IFNg+ cells (0.5–3.5% of gated lymphocytes across all samples), we obtained an average of 
739 unique productive clonotypes from 114111 reads per individual.
Gluten-specific CD4+ IFNg+ TCRB repertoires are as diverse as total patient PBMC repertoires 
while patient gut repertoire diversity is increased during active CD. Significant changes in diversity 
following antigen exposure indicate uneven shift in repertoires, such as mono-, oligo- or poly- clonal expansion, 
with possible implications in disease development19,20. To evaluate TCR repertoire diversity and avoid possible 
bias due to differences in sequencing depth, we downsampled all samples to 27077 reads (the size of the second 









CD005 CD F 61 DQ2.5/DQ2.5 GFD 1 yr negative Wheat 3d PBMC 1,2
CD006 CD F 61 DQ2.5/DQ5 GFD 16 yr negative Wheat 3d PBMC 1
CD0011 CD M 55 DQ2.5/DQ8 GFD 10 yr negative Wheat 3d PBMC 1
CD0039 CD F 55 DQ2.5/DQ2.2 GFD 2 yr negative Wheat 3d PBMC 1,2
HC014 HC F 30 DQ2.5/DQ6 GFD 4 wk negative Wheat 3d PBMC 1
HC036 HC F 52 DQ2.5/DQ6 GFD 4 wk negative Wheat 3d PBMC 1
CD037 CD F 50 DQ2.5/DQ6 GFD NA negative Wheat 3d PBMC 2
CD025 CD F 25 DQ2.5/DQ2.5 GFD 6 yr negative Barley 3d PBMC 2
CD027 CD F 40 DQ2.5/DQ2.5 GFD 1 yr negative Barley 3d PBMC 2
CD034 CD F 58 DQ2.5/DQ5 GFD 5 yr negative Rye 3d PBMC 2
CD042 CD F 65 DQ2.5/DQ5 GFD 27 yr negative Rye 3d PBMC 2
CD044 CD F 64 DQ2.5/DQ6 GFD 7 yr negative Rye 3d PBMC 2
CD1GB CD F 67 DQ2/DQ6 AD/GFD 1 yr 90/neg NA Biopsy 3
CD2GB CD F 47 DQ2/DQ6 AD/GFD 1 yr 57/neg NA Biopsy 3
CD3GB CD M 56 DQ2/DQ6 AD /GFD 1 yr 21/neg NA Biopsy 3
CD4GB CD F 20 DQ2/DQ2 AD /GFD 1 yr 44/neg NA Biopsy 3
CD5GB CD F 39 DQ2/DQ2 AD /GFD 1 yr >100/neg NA Biopsy 3
Table 1. Information on the study subjects and the treatment conditions for the experiments. *tTG IgA 
negative: <5 U/ml.
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smallest sorted repertoire). For each repertoire, the median of 100 diversity estimates from 100 downsamples was 
used for analysis.
The sorted CD4+ IFNg+ samples did not show any difference in diversity compared to the highly diverse pre- 
and post- challenge total patient PBMC repertoires (Fig. 1), suggesting high diversity in the sorted gluten-specific 
TCR repertoires. CD patient post-challenge total PBMC repertoires showed no change in diversity compared 
to their pre-challenge repertoires. Interestingly, although not statistically significant, all CD patient gut biopsy 
repertoires showed increased diversity during active disease, with a median increase in diversity of 6% (range: 
1.9–7.9%) in biopsies before commencing GFD compared to biopsies collected one year after commencing GFD 
(Wilcoxon Signed Rank Test, P = 0.06, Fig. 1).
Gluten exposure induces substantial TRBV gene usage perturbation. We found no statistically 
significant difference in mean TRBV gene usage between all post- versus pre- challenge PBMC repertoires, and 
between all GFD-treated versus active disease gut biopsy repertoires (measured either from unique sequences 
to analyze overall TRBV gene usage or from total reads to detect expanding/contracting genes) (Supplementary 
Figure S2). To investigate this further in each individual, we compared TRBV gene usage between the gluten 
exposed and unexposed repertoires for each subject. When considering unique clonotypes,TRBV5, TRBV6, 
TRBV7 and TRBV18 family genes were more frequently used in patient total PBMC repertoires after gluten chal-
lenge while only TRBV6 showed increased usage in one patient’s biopsy repertoire during active CD (Fig. 2A and B; 
for all TRBV-gene results see Supplementary Fig. S3). There were no V gene usage differences between unique 
clonotypes in the sorted and the unsorted repertoires in the two patients CD005 and CD039, from whom 
we had both sorted and unsorted repertoire data. Importantly, however, substantial TRBV gene usage per-
turbation was observed when the analysis was performed using total reads (Fig. 2C and D, Supplementary 
Figure S3). Particularly for the sorted repertoires, strong over-usage of genes was observed in the TRBV18, 
TRBV19, TRBV29 and TRBV30 families, in addition to those previously reported in TRB6 and TRB79–11,15,16,21 
(Supplementary Figure S3E). Overall, TRBV gene usage comparison using total reads (representing all T-cells) 
detected skewed TRBV gene usage in patients due to antigen induced clonal expansion from the available pool 
of unique clonotypes.
Gluten exposure is associated with increased repertoire overlap between CD patients. To 
assess the effect of gluten exposure on amino acid clonotype sharing between individuals, we compared the 
inter-individual repertoire overlap between pairs of gluten unexposed repertoires to that of pairs of gluten 
exposed repertoires. Patient PBMC samples did not show significant difference in overlap after gluten chal-
lenge, despite a marginal increase (Fig. 3A). In contrast, there was significantly increased overlap among patient 
gut biopsy repertoires during active disease compared to biopsies taken after one year GFD (Wilcoxon Signed 
Rank Test, P = 0.01, Fig. 3A). We also observed increased overlap from the combined comparison of all pairs 
of patient PBMC and GUT repertoires (Fig. 3C), indicating that the gluten induced public clones in blood are 
at least partly the same as those residing in the gut even in unrelated patients. These results overall suggest that 
increased repertoire overlap among patients is a feature of the immune response to gluten. On the other hand, 
Figure 1. TCR repertoire diversity in gluten exposed CD patients. (a) No difference in repertoire diversity is 
observed between gluten specific CD4+ IFNg+sorted TCRB repertoires and pre- (day0) or post- challenge 
(day6) CD patient PBMC repertoires. Gut repertoires show interesting increase in diversity (decrease in 
clonality) during gluten exposure (Wilcoxon paired Signed Rank test, two-tailed, p = 0.06; paired t-test, two-
tailed, p = 0.0077. The p-value from the t-test is shown here since the Wilcoxon signed rank test has limitations 
when applied to small sample size even though it is the main test employed in this study). Repertoire samples 
were downsampled to 27077 reads 100 times, each time estimating diversity. For each sample, median of the 
100 diversity estimates is used for plotting and statistical comparison. Horizontal bars indicate median. (b) 
The diversity increase in active CD gut repertoires ranged from 1.9 to 7.9% (median: 6%) of the treated gut 
repertoire diversity in patients.
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this increasing overlap was not seen when using nucleotide clonotypes for the analysis (Fig. 3B), possibly due to 
the gluten-induced higher repertoire diversity at the nucleotide level, detectable number of which is likely coding 
for the same amino acid clonotypes which are shared among patients.
Differential abundance (DA) analysis identifies gluten-induced and -specific T-cells. We applied 
the first DA analysis approach (described in the Methods section) to identify DA clonotypes in each individual. 
For the four patient PBMC repertoires, we found a median of 448 enriched (range: 216–465) and 355 de-enriched 
(range: 226–808) clones following gluten challenge while the two healthy controls had 243 enriched (range: 
241–245) and 393 de-enriched (range: 157–628) clonotypes. For the five gut biopsy repertoires, a median of 
631 enriched (range: 384–1130) and 941 de-enriched (range: 466–1127) clonotypes were observed during active 
disease. These results give a putative estimation of the amount of gluten-induced T-cell clonotypes, which we 
defined as clonotypes showing significant change in clonal size as a result of gluten exposure regardless of their 
specificity (Fig. 4).
For the two patients (CD005 and CD039) that had sorted and unsorted repertoires, DA clones identified from 
their sorted repertoires, compared to their unsorted pre-challenge and post-challenge samples, showed low over-
lap with those detected from the comparison of their unsorted post-challenge versus pre-challenge repertoires 
(Supplementary Table S2 and Figure S4). Since DA clonotypes identified from sorted CD4+ IFNg+ repertoires 
are specific to gluten, the low overlap perhaps indicates that the T-cells specific to the 3 immunodominant gluten 
peptides among in vitro stimulated sorted clones represent only a fraction of all clonotypes enriched after in vivo 
gluten challenge, the latter including both gluten specific and non-specific T-cells. We also found little overlap in 
gluten-induced DA clones across patients, despite the increased overlap in patient total repertoires during gluten 
exposure (Fig. 3B and Supplementary Figure S4).
Given the observation that gluten exposure increased inter-individual repertoire overlap, we applied the sec-
ond DA analysis approach (see Methods section) and evaluated the differential abundance of 11834 public clo-
notypes that were observed in at least two different individuals (constituting 4.7% of the total 251259 unique 
amino acid clonotypes available in all samples). This analysis was performed separately for the CDPBMC (n = 4), 
HCPBMC (n = 2), and CDGUT (n = 5) repertoires (Table 2). From the resulting public DA clones, only two of 
the public enriched DA clonotypes (CASSLGDTQYF and CASSFSYEQYF) from patient PBMCs overlapped to 
those detected from healthy PBMCs, and one (CASSLTWDTEAFF) to those detected from patient gut repertoires 
(Supplementary Figure S4). More than half of the public DA clonotypes were among the recently published 10692 
representative public TCRB clonotypes (repPC)14, indicating possible clinical utility in maintaining detailed 
repository of public TCR clonotypes and their specificities. The list of public enriched clonotypes is available in 
the supplementary dataset 1.
We also investigated the presence of previously reported gluten reactive TCRB CDR3 clonotypes7,11,15 in our 
public DA clonotypes. We found 4 previously reported clonotypes: CASSLRSTDTQYF, CASSFRSTDTQYF, 
CASSIRHTDTQYF and CASSLNWDTEAFF among enriched clones in patient PBMCs, and CASSLGYEQYF 
among enriched clones in patient gut repertoires. We did not find any previously known clonotype in the 
Figure 2. TRBV gene usage is substantially perturbed upon gluten exposure in CD patients. TRBV gene usage 
in treated versus untreated repertoires is shown for selected gene segments. Heat maps show differentially used 
TRBV genes in at least one patient (fisher’s exact test, BH adjusted p-values < 0.05), numbers are p-values, 
green shows odds ratio (OR) > 1 (over-representation) and red OR < 1 (under-representation) during gluten 
exposure. (a) and (b) show the result for patient PBMC and gut repertoires respectively when TRBV gene usage 
is compared at unique clonotypes. (c) and (d) for patient PBMC and gut repertoires respectively when TRBV 
gene usage is compared using all reads.
www.nature.com/scientificreports/
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de-enriched clonotypes of patient PBMC repertoires and enriched/de-enriched clones of healthy control PBMC 
repertoires (Table 2), consistent with the assumed gluten-specificity of these clones. Next, we examined sequence 
similarity between public DA clonotypes to identify conserved structures. Hierarchical clustering of the 33 
enriched CDPBMC clonotypes resulted in five clusters. The top cluster had a significant over-representation 
of the MEME regular expression motif ASS[LF]R[SW][TD][DT][TE][QA][YF] (Fig. 5). The same analysis 
for the de-enriched clonotypes resulted in six clusters with the top cluster showing no significant motif. We 
found no over-represented motif in the top cluster of the enriched HCPBMC as well as CDGUT repertoires 
(Supplementary Figures S5–8.
We further sought to explore the contribution of public clonotypes in the immune response to gluten. Of the 
gluten-induced DA clonotypes in each individual as determined by approach one, 10% to 15% were also present 
in our set of public clonotypes, accounting for an average of approximately 40% and 20% of the cells (reads) in 
the enriched DA clones of the CDPBMC and CDGUT respectively (Supplementary Table S2 and Figure S9). This 
estimates the amount of public clonotypes involved in gluten response in each individual, and does not neces-
sarily reflect consistency in response behavior of the clonotypes across patients since most of these clonotypes 
are not detected from the analysis using approach two. Interestingly, compared to the private DA clonotypes of 
each patient, higher rate of convergent selection (multiple nucleotide clonotypes coding for identical amino acid 
clonotype) appears to be a feature of these ‘public subset’ of the DA clonotypes with an increasing trend during 
gluten exposure (Supplementary Figure S10).
Figure 3. Inter-individual repertoire overlap comparison. (a) Increased inter-individual amino acid repertoire 
overlap is observed in gut biopsy samples during gluten exposure (n = 10 possible pairs at each time point for 
the 5 CD GUT samples, Wilcoxon paired Signed Rank test, **p = 0.01), while CD patient PBMC repertoires 
show non-significant increase in overlap. (b) No increased inter-individual overlap is observed in the nucleotide 
repertoires of both PBMC and gut biopsy samples during gluten exposure. (c) Inter-individual repertoire 
overlap for combined data (4 CD PBMC and 5 CD GUT samples, n = 36).The evidence for public component 
in the response to gluten is stronger when repertoire types are combined for the overlap analysis, showing even 
higher inter-individual repertoire overlap between unrelated individuals and repertoires drawn from separate 
tissues (Wilcoxon paired Signed Rank test, **P = 0.0002). PBMC-gut pairs show significantly increased overlap 
during gluten exposure (Wilcoxon paired Signed Rank test, **P = 0.0064). Horizontal bars indicate median. 
Patient PBMC pairs are in triangles, gut biopsy pairs are in circles, mixed pbmc-gut pairs are in rectangles.
www.nature.com/scientificreports/
6SCIEnTIFIC RepoRTS |  (2017) 7:17977  | DOI:10.1038/s41598-017-18137-9
Discussion
Over the last few years, the T-cell repertoire of various autoimmune diseases has been analyzed using non-biased 
targeted deep sequencing approaches. In the present study, we have utilized T-cell repertoire deep sequencing and 
investigated the immune repertoire in gluten exposed CD patients. We profiled and characterized global immune 
repertoire features in peripheral blood in patients following a short 3-day gluten exposure, and in the gut during 
active CD. We also identified and characterized clonotypes that showed clonal expansion (or contraction) during 
gluten exposure.
In our study, the immune repertoire during gluten exposure was generally diverse in both PBMC and gut. We 
did not detect an alteration of the high TCR diversity observed in CD patient PBMC repertoires. Gluten-specific 
peripheral CD4+ IFNg+ TCR repertoires were also similar in diversity to the total unsorted patient PBMC 
repertoires, suggesting high poly-clonality in the CD4+ T-cell response specific to gluten. Hardy et al. have 
reported such diversity at the TCR level in a smaller repertoire of CD4+ IFNg+ T-cells specific to the dominant 
HLA-DQ2.5-glia-α1a/α2 epitope in both children and adult CD patients, with adult patients not showing any 
more narrowing of the repertoire specific to the epitope compared to that of children despite more exposure to 
gluten18. The high TCR diversity is also consistent with the cross-reactivity of the gluten-specific T-cells, in which 
T-cells bearing diverse TCRs are directed to specific immuno-dominant gluten peptides and their homologs5,18.
In active CD patient gut biopsies, there was an increase in diversity (by an average of 6%) compared to the 
treated repertoires after one year, confirming reports that have found higher repertoire diversity in active CD 
patient biopsies22. The increased diversity in the gut reflects the massive increase in mucosal infiltrating T-cells 
Figure 4. Enriched and de-enriched clonotypes in each subject. Differential abundance analysis between the 
gluten unexposed and gluten exposed repertoires of each subject was performed. (a) Left panel, the analysis 
determined a median of 448 enriched (i.e., substantially higher frequency) (range: 216–465) and 355 de-
enriched (i.e., substantially lower frequency) (range: 226–808) clones following gluten challenge in CD patient 
PBMC repertoires. In healthy controls, 243 enriched (range: 241–245) and 393 de-enriched (range: 157–628) 
clonotypes were estimated. For gut repertoires, for which samples were taken one year apart, an average of 631 
enriched (range: 384–1130) and 941 de-enriched (range: 466–1127) clonotypes were observed during active 
disease. Right panel, the number of both enriched and de-enriched unique amino acid clonotypes relative to the 
total number of all unique amino acid clonotypes observed in the two repertoires of each subject is shown. (b) 
The relative clonal size (relative to total sequencing reads) of the enriched and de-enriched clonotypes, before 
and after gluten exposure. For both enriched and de-enriched, the combined clonal size of the DA clonotypes in 
each subject is shown. Horizontal bars indicate median.
www.nature.com/scientificreports/
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in active CD. It was probably possible to detect this change in the gut due to the relatively stable nature of the 
gut repertoires, in addition to the gut being the main site of inflammation and/or the longer gluten exposure 
(Supplementary Figure S11). In general, the immune response associated with gluten exposure appears to 
involve a diverse set of T-cell clonotypes directed to gluten, and other possible unidentified antigens involved 
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CDPBMC 70 33 4 33 11 33 17 14 14 3 1 1 21
HCPBMC 95 95 5 51 26 36 37 26 24 0 0 0 47




CDPBMC 75 38 3 38 38 16 18 10 17 0 0 0 22
HCPBMC 102 101 4 56 35 36 46 29 31 0 0 0 53
CDGUT 45 0 0 0 0 0 0 0 0 0 0 0 0
Table 2. Differential abundance analysis results on public clonotypes. +RankProduct(RP) results from 
approach two in the DA analysis. *Sequential forward feature (SFS) selection applied on the RP output resulting 
in differentially abundant (DA) clonotypes.
Figure 5. Public differentially enriched CD patient PBMC clonotypes. (a) DA clonotypes are enriched in post-
challenge CD patient samples (color intensity indicates prevalence level), their prevalence in healthy control 
pre- and post-challenge samples is also shown for comparison. The donut plot on the right shows the TCRBV 
genes used by these DA clonotypes in CD patient post-challenge samples, from the least to the most used. 
Clonotypes were hierarchically clustered using a modified Levenshtein distance that took physicochemical 
properties into account; the cluster indicated with the green bar has the highest average fold change increase 
during gluten exposure. (b) MEME motif search of the top cluster: significantly over-represented motif shown 
in sequence logo and regular expression, ASS[LF]R[SW][TD][DT][TE][QA][YF] (E-value = 2.4E-10); Top 
cluster contains previously known HLA-DQ2 restricted, alpha gliadin epitope specific CD4+ clonotypes with 
the ASSxRxTDTQY motif (highlighted with light green).
www.nature.com/scientificreports/
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gluten influence on microbiota. Chemokines secreted by the inflammatory cells in active CD could also attract 
“by-stander” T-cells of many other specificities unrelated to gluten to the site of inflammation.
Gluten exposure led to substantial perturbation of the V-gene usage in both the PBMC and gut repertoires 
in each patient, mainly due to proliferative changes of the available unique clonotypes. We observed significant 
over-usage of genes in various TRBV gene families in one or more patients resulting from clonal expansion. We 
also observed significant alterations in previously reported TRBV genes that are preferentially selected for specific 
immuno-dominant gliadin epitopes7,10,11,16, such as TRBV07-02 (over-used in all patient PBMC repertoires and 
two gut repertoires) and TRBV04-02 (over-used in four gut repertoires and two PBMC repertoires). Similar anal-
yses of the unique clonotypes suggested that patient repertoires maintained a V-gene usage profile that remained 
more or less stable before and after gluten exposure, particularly in the gut, likely an indication of clonal persis-
tence in the available immune repertoire.
Inter-individual repertoire overlap was significantly increased among patients during gluten exposure, par-
ticularly in the gut, suggesting that the immune response to gluten is characterized by a public component. The 
evidence for the increased repertoire overlap was even more pronounced when we combined patient gut and 
PBMC repertoires and compared them to their treated counterparts. While semi-public response to specific 
immuno-dominant gluten epitopes have been previously reported7,11, our data shows that increased amino acid 
repertoire sharing among CD patients can be detected from the total repertoire (across tissues, and after both a 
short gluten challenge or long-term gluten exposure) and is likely a major feature of the immune response in CD.
We identified hundreds of differentially abundant clonotypes with significantly altered prevalence during 
gluten exposure from total repertoires of each individual, both in patients and healthy controls. DeWitt et al.23 
showed that DA clonotypes identified in such manner, i.e. by comparing multiple total repertoires of an indi-
vidual, captured approximately 60% of known antigen-specific CD8+ cells, whose response magnitude is much 
higher compared to CD4+ T-cells, in a model of acute viral infection. Since our repertoire data contain response 
signals coming from both CD8 and CD4 T-cell populations, our estimates are only a rough approximation, possi-
bly an upper bound, of the frequency of gluten-induced T-cells. From these results, we observed that the immune 
reaction to gluten involved a large private component; public clonotypes constituted between 10–15% of the 
differentially abundant clonotypes and had an increased rate of convergent selection during gluten exposure. The 
role and significance of the gluten-induced public clonotypes compared to those that are private in CD pathogen-
esis is unclear. Public clonotypes are generally less complex and more abundant24; TCR sequences that are more 
likely to be produced in the thymus also pass thymic selection more often25, indicating that positive selection of 
some abundant public clonotypes to the periphery may have a crucial immunological importance. Public clo-
notypes in mice have been shown to frequently harbor autoimmune specificities26,27. They have been shown to 
have capacity for cross-reactivity, as well as specificity to self and foreign antigens28. Self-reactive T-cells have also 
been associated with more efficient response to foreign antigens in terms of response rates, clonal expansion size 
and sensitivity to inflammatory signals29. Overall, while public clonotypes are likely crucial for efficient immune 
response, dysregulation of their functions may lead to aberrant self-immunity.
By examining changes in the prevalence of a selected set of public clonotypes, we identified enriched public 
clonotypes across CD patients in PBMC and gut repertoires. Only one clonotype was shared between the public 
enriched DA clonotypes of PBMC and gut, possibly due to the differences in the duration of gluten exposure or in 
the abundance of various T-cell subsets in each compartment; of note, CD patient gut repertoires are dominated 
by cytotoxic gluten-independent intestinal intraepithelial lymphocytes (IELs) during active disease30. In patient 
PBMCs, the amino acid pattern ASS[LF]R[SW][TD][DT][TE][QA][YF] with conserved usage of the arginine 
at the fifth position, generalizing previously reported motif ASSxRxTDTQY, was over-represented in the most 
proliferative cluster of enriched clonotypes, which also contained clonotypes that were exactly identical to the 
previously reported gluten specific T-cell clones10. The arginine residue in gluten reactive clonotypes has been 
shown to be very crucial in the immune response9,11,21. The dominance of such arginine bearing clonotypes is 
reduced among the public enriched clonotypes of the gut, possibly suggesting that the public clonotypes specific 
to the highly immunogenic epitopes play an important role mainly in the early response to gluten exposure. This 
observation of increased arginine bearing clonotypes following gluten exposure is also detectable in total patient 
PBMC repertoires but not in total gut repertoires, particularly during active disease (Supplementary Figure S12). 
With prolonged exposure to gluten, at least in the gut, the prevalence of arginine bearing gluten reactive clono-
types may wane, with patient gut repertoires becoming increasingly more diverse and dominated by infiltrating 
T-cells with clonotypes directed to other antigens. It is possible that arginine bearing gluten reactive public clo-
notypes may commit to long term-memory more often, as they likely have strong functional avidity to gluten 
epitopes evidenced by their strong enrichment31,32. Once gluten tolerance is broken, these T-cells could be among 
those that trigger the early adaptive response to gluten upon re-exposure.
This study used small number of samples; the PBMC and gut samples were also not from the same patients. 
Larger number of samples would have allowed a more representative comparison of repertoires, while matched 
samples would have provided the possibility to track gluten reactive clonotypes in both compartments. In our 
experimental setup, we mainly wanted to explore the impact of gluten exposure to the total repertoire in-vivo, 
which also reflects possible reaction driven by T-cell subsets other than T-helper cells (such as regulatory T-cells, 
and CD8+ T-cells for which the antigen specificity is unknown), although we did not further study their pheno-
types. Thus, the gluten-induced clonotypes we found were not necessarily specific to gluten, but could have been 
due to secondary effects of its ingestion. Therefore, it would be very informative to study in future the complete 
profile of the interesting public clonotypes identified, such as their full TCRαβ pairing and gene expression pat-
terns using for instance single cell analysis methods. In spite of these limitations, we were able to identify major 
immunological signatures associated with gluten exposure, identify gluten-induced clonotypes from total patient 
repertoires, and estimate contributions of private and public clonotypes to the gluten-induced immune response 
in patients.
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In summary, gluten exposure appears to elicit diverse reaction at the TCR level particularly in the gut, and in 
PBMC as evidenced by the high TCR diversity observed in the gluten specific PBMC CD4+ IFNg+ repertoires. 
Increased repertoire overlap was seen in unrelated patients, and the immune response in general was character-
ized by a large private and an important public component. Deeper level of repertoire sequencing with large num-
ber of samples could enable identification and tracking of disease associated public clonotypes or immunological 
signatures, with potential applications such as early diagnosis, disease and treatment monitoring, and patient 
stratification based on factors such as patient HLA-types and clinical symptoms.
Methods
Subjects and study design. The study participants who provided blood or intestinal biopsy material 
are presented in Table 1. All subjects were positive for the high-risk CD-associated susceptibility alleles HLA-
DQA1*05 and HLA-DQB1*02 encoding HLA-DQ2.5.
In CD subjects, the diagnostic criteria were duodenal villous atrophy accompanied by elevated serum 
anti-tissue transglutaminase IgA. For the first two experiments, gluten challenges, blood collections, isolation 
of PBMC and overnight IFN-γ ELISpot were performed according to Anderson et al.4 and Tye-din et al.5. CD 
subjects on long-term GFD consumed one of wheat bread (4 slices, equivalent to approximately 10 g/d gluten), 
barley flakes (120 g/d, equivalent to approximately 8 g/d hordein), or rye bread (equivalent to approximately 8 g/d 
secalin). In addition, two healthy subjects who had excluded food with gluten for 4 weeks completed the same 
3-day wheat bread challenge. PBMCs were isolated from blood collected immediately before commencing gluten 
challenge (day 0) and 3 days after completing gluten challenge (day 6). PBMCs were either cryopreserved or used 
to measure responses to gluten-derived peptides stimulatory for CD4+ T cells in overnight IFN-γ ELISpot assays. 
In the first experiment, DNA was extracted from frozen PBMC stocks collected before and after wheat gluten 
challenge from 4 CD donors with positive IFN-γ ELISpot responses to gluten peptides, and 2 healthy donors, for 
bulk TCR analysis. In the second experiment, PBMC collected from 8 CD donors 6 days after commencing gluten 
challenge with wheat (n = 3), barley (n = 2), or rye (n = 3) were thawed, and incubated with a mixture of three 
immunodominant gluten peptides (for antigen presentation by mainly B-cells) to identify CD4+ T cells secreting 
IFN-γ (see below for details). TCR analysis was performed on CD4+ IFNg+ cells sorted by flow cytometry. In 
the third experiment, TCR analysis was performed on DNA isolated from fresh 2nd part duodenal biopsies from 
5 additional CD patients at the time of diagnosis during active disease and again after one year GFD treatment.
Ethics. The study design and recruiting of patients were approved by the Ethics Committees of the Pirkanmaa 
Hospital District, Finland. All subjects gave written informed consent. Relevant guidelines and regulations were 
followed when performing the experiments.
Isolation of gluten-specific IFNg-producing T cells. The cryo-preserved PBMC samples were thawed 
by resuspension into complete RPMI, and re-stimulated, after a resting period of 60 min at 37°C, with a pool 
of 3 immunodominant gluten peptides (LQPFPQPELPYPQPQ “DQ2.5-glia-α1a & α2”, QPFPQPEQPFPWQP 
“DQ2.5-glia-ω1 & ω2” and PEQPIPEQPQPYPQQ “DQ2.5-hor-3”)5,33, each in a final concentration of 100 micro-
gram/ml. After 16 h, cells were resuspended in PBS, and incubated with IFNg catch reagent, followed by staining 
with PE anti-IFNg detection antibody (IFNg secretion assay kit; Miltenyi Biotech) and FITC anti-CD4 antibody 
(clone OKT4; Biolegend), according to manufacturer’s instructions. IFNg secreting CD4+ T cells were separated 
by FACS sorting, using a BD Facs Aria II instrument. Cells were also stained for gut-homing marker CCR9 in 6 of 
the 8 samples, which showed that the selected CD4+ IFNg+ population was enriched with cells expressing CCR9 
compared to CD4+ IFNg− cell fraction (84% vs 40%, Supplementary Figure S13). DNA was extracted from the 
sorted cell pellets using a DNA/RNA extraction kit (Qiagen).
DNA extraction and Sequencing. DNA was extracted (AllPrep DNA/RNA Mini Kit, Qiagen) from 2-10 
million pelleted and lysed pre- and post-challenge cell samples of 4 wheat challenged and wheat epitope respond-
ing patients, as well as from 2 non-responding healthy controls. For gut samples, total DNA was extracted from 
snap frozen biopsy specimens, obtained at the time of diagnosis of 5 DQ2 + CD patients with untreated, active 
disease and confirmed mucosal lesions, as well as biopsies of the same 5 patients after 1 year of gluten-free diet 
(GFD), using QIAamp Mini Kit (Qiagen, Valencia, CA) as described in Wacklin et al.34.
DNA samples (1ug per sample) were sent to Adaptive Biotechnologies and were deep sequenced for TCRB 
CDR3 region (Seattle, USA, www.adaptivebiotech.com; www.immunoseq.com) with their ImmunoSeq assay 
which employs optimized multiplex PCR to target and amplify the TCR CDR3 region and Illumina for sequencing35. 
For each unique TCRB CDR3 sequence in a sample, the nucleotide and predicted amino acid sequence, the 
re-arranged V D and J genes, and the number of sequencing reads were determined.
Sequence data and statistical analysis. Productive sequences without frameshift mutations or stop 
codons, constituting ~ 80% of our repertoires, were used in all subsequent analyses. We employed downsampling, 
pre-processing, and data normalization procedures appropriate for each analysis as described in the respective 
sections. All analyses were done in R (https://www.r-project.org/) and graphs were made using R and Prism 6.0 
(GraphPad Software, La Jolla California USA, www.graphpad.com).
Repertoire diversity was estimated using the Shannon entropy index normalized by total number of unique 
amino acid clonotypes, −∑ ⁎ ⁎ C N( C log2( ))/(log2( ))i i i  where Ci is the relative frequency of unique clonotype i in 
the repertoire, and N  is the total number of unique amino acid clonotypes. A normalized entropy value of 1 
reflects high diversity while 0 reflects low diversity. The diversity of every sample was estimated as the median of 
100 diversity values calculated from 100 downsampling of each sample to 27077 reads (the size of the second 
smallest sorted repertoire). Diversity comparison between groups was mainly performed using the 
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non-parametric Wilcoxon Signed Rank Test as assumptions for parametric tests could not be established with the 
small sample size in this study. But, we also used the parametric paired t-test for some of the analysis since 
Wilcoxon Signed Rank test has limitations for small sample sizes. For both cases, p-values less than 0.05 were 
considered significant.
TRBV gene usage was compared between groups of gluten exposed/unexposed repertoires and between the 
two repertoires of each individual, using information obtained from either unique clonotypes or total reads in 
repertoires. Comparison between groups was performed using Wilcoxon Signed Rank Test (paired or unpaired as 
appropriate) with Benjamini–Hochberg (BH) adjusted p-values less than 0.05 considered significant. Comparison 
between different repertoires sampled from an individual was done using fisher’s exact test with BH adjusted 
p-values < 0.05 considered significant.
Inter-individual repertoire overlap was calculated for every possible pair of repertoires at each time point 
using:
O 2 [c/(a b)] (1)= × +
where O is the estimated inter-individual repertoire overlap between the repertoires, c is the number of 
identical amino acid clonotypes between the TCR repertoires, a is the number of unique amino acid clono-
types in one of the repertoires, and b is the number of unique amino acid clonotypes in the other repertoire. 
To avoid possible bias due to differences in sequencing depth, the overlap was estimated as the median of 
100 overlap estimates, each calculated after randomly downsampling both repertoires to the total number of 
sequence reads in the smaller repertoire. The overlap was then compared between groups using Wilcoxon 
Signed Rank test (paired or unpaired as appropriate) with p-values less than 0.05 considered statistically 
significant.
Differential abundance (DA) of clonotypes between conditions was performed to identify putative 
gluten-induced clonotypes whose frequencies differed because of gluten exposure. DA was assessed using two 
approaches: one was used for identification of DA clonotypes in an individual between repertoires sampled at 
different time points, and another for identification of public DA clonotypes across individuals by comparing 
groups of gluten exposed and unexposed repertoires. For approach one, we implemented the fisher’s exact test 
based-algorithm used for DA analysis by DeWitt et al.23. In brief, amino acid clonotype abundances were com-
pared between repertoires of an individual sampled at different time points using fisher’s exact test. We adjusted 
p-values of the shared clonotypes between the two time points using Benjamini–Hochberg (BH) and consid-
ered clonotypes with adjusted p-values less than 0.01 differentially abundant. We divided the set of DA clono-
types resulting from this analysis into enriched and de-enriched sets based on their frequencies in the compared 
repertoires
In approach two, we used the Rank product36 combined with sequential forward feature selection (SFS) to 
identify public DA clonotypes across patients. Briefly, a clonotype abundance (clonotype count frequency) matrix 
was prepared for public amino acid clonotypes, which we defined as clonotypes seen in at least two different 
individuals across all repertoire types: namely, CD patient PBMC repertoires (CDPBMC), Healthy control PBMC 
repertoires (HCPBMC), Sorted sample repertoires (Sorted) and CD patient Gut repertoires (CDGUT). After 
data normalization, separate two-class rank product analysis was performed using RankProd37 for the paired 
CDPBMC (n = 4), HCPBMC (n = 2), and CDGUT (n = 5) samples. RankProd first ranks clonotypes according 
to their frequency fold change in the two repertoires sampled from each subject. Next, it computes rank product 
(RP) for each clonotype across subjects (the geometric mean of the ranks for the clonotype across individuals). 
It is unlikely that a clonotype has a top ranking fold change consistently in all replicate experiments by chance, 
i.e. clonotypes with smallest RP, that result from consistent top ranking in replicate experiments, are likely to be 
enriched or de-enriched clonotypes of interest (depending on the ranking order of the fold changes). The method 
identifies these differentially abundant features using a permutation test, by estimating the probability of the RP 
happening by chance for each clonotype. We further filtered the list of clonotypes showing enrichment (i.e., have 
substantially higher frequency) or de-enrichment (i.e., have substantially lower frequency), with RP p-values less 
than 0.01, using sequential forward feature selection (from the most significant to the least) to reduce possible 
false positives. In this step, we selected the first n clonotypes with a leave-one-out cross validation38 error less or 
equal to 0.25 when used in a random forest classification model for prediction of sample’s gluten exposure status. 
Clonotypes that passed this filter were considered differentially abundant (DA) and were next subjected to cluster 
analysis. Detailed description of this second approach is available in the supplementary ‘Clonal differential abun-
dance analysis procedure’ section (see also Supplementary Figure S1).
Hierarchical clustering of public DA clonotypes was performed using a modified Levenshtein distance 
(LD) to estimate pairwise clonotype similarity, by taking into account differences in sequence length and phys-
icochemical properties. The approach combined methods used in previous studies39–41. The physicochemical 
properties were evaluated using hydrophobicity according to the Kyte and Doolittle scale42, acidity according 
to the isoelectric point(PI) and molecular mass(Da) of the amino acids constituting the CDR3 sequences. 
For each amino acid clonotype, we used the mean property of the amino acids making up the clonotype to 
represent the clonotype’s overall propensity for that property. Similarity between any two DA clonotypes was 
then estimated using LD, modified by their difference in length, mean acidity, hydrophobicity, and weight as 
follows:
∆ ∆ ∆ ∆ = + + + +
(2)
Modified LD (LD sequence_lengths mean_Acidity mean_Hydrophobicity mean_Wt)/
(Edit path length)
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The pairwise similarity matrix using this measure was then hierarchically clustered; the dendrogram was cut 
dynamically43 and the resulting clusters were assessed for average fold change values. The cluster containing clo-
notypes with the highest average fold change was considered the ‘top cluster’. Clonotypes in the top cluster may 
be considered the most likely proliferative candidates driving the public component of the immune response to 
gluten. MEME44 was used to search for over-represented sequence motifs for clonotypes in each cluster.
Data availability. The datasets and R scripts used in the current study are available from the corresponding 
author on reasonable request.
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